CoreRx has added an Xcelodose precision powder micro-dosing system to its product development capabilities for preclinical and early phase clinical GMP supply. According to the company, the Xcelodose decreases processing time and API use, generating significant cost savings to clients.

“CoreRx is continually assessing and investing in solutions to accelerate the manufacturing of our client’s clinical supplies, while ensuring quality at all times,” said Mark Licarde, CoreRx’s vice president of manufacturing. “While CoreRx has always offered API in capsule, we now see examples of some clients maintaining this approach through to Phase II studies in an attempt to compress their overall development timelines, requiring significant quantities of capsules for which an automated solution is best. CoreRx is the only CRO in the world with a full set of Xcelodose change parts all the way down to size nine.”

The Xcelodose system, manufactured by Capsugel, is a precision powder micro-doser and automated encapsulator that has the ability to fill formulations or API directly into capsules with a high level of accuracy. The system can dispense amounts as low as 100 micrograms and as high as 100 milligrams and beyond, into capsules from size 00 to size nine.